论文部分内容阅读
palbociclib是辉瑞制药有限公司(Pfizer)研发的选择性CDK4/6抑制剂,2015年2月3日,基于临床试验证明的无进展生存期(PFS),FDA采用加快审评途径批准其上市,与来曲唑(Letrozole)联合使用作为以内分泌治疗为基础的初始方案,用于治疗雌激素受体阳性(ER+)、人表皮生长因子受体2阴性(HER2-)的绝经女性乳腺癌。笔者对其基本性质、作用机制、药代动力学、药物相互作用、临床研究、不良反应及国内研发现状等方面做一综述。
palbociclib is a selective CDK4 / 6 inhibitor developed by Pfizer. On February 3, 2015, based on clinical trials demonstrating progression-free survival (PFS), FDA approached its IPO by expediting the review process, Letrozole is used as an initial endocrine-based regimen for the treatment of postmenopausal women with estrogen receptor positive (ER +) and human epidermal growth factor receptor 2 (HER2-) cancers. The author reviews its basic properties, mechanism of action, pharmacokinetics, drug interactions, clinical studies, adverse reactions and the status of domestic research and development.